YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study
Fig 3
Distribution of cases into to TRG classes according to YKL-40 immunoreactivity (A) and overexpression of YKL-40 in the non-responder group (TRG2-5) when considered both as continuous (B) and categorical variable (C).